BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 1333371)

  • 21. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
    Johnson FM; Kurie JM; Peeples BO; Lee JJ; Feng L; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS
    Clin Lung Cancer; 2003 Jul; 5(1):40-5. PubMed ID: 14596703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase II trial of cisplatin and prolonged administration of oral etoposide in extensive-stage small cell lung cancer.
    Murphy PB; Hainsworth JD; Greco FA; Hande KR; DeVore RF; Johnson DH
    Cancer; 1992 Jan; 69(2):370-5. PubMed ID: 1309432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolonged administration of oral etoposide plus cisplatin in extensive stage small cell lung cancer.
    Greco FA; Murphy PB; Hainsworth JD; Hande KR; Johnson DH
    Oncology; 1992; 49 Suppl 1():34-8; discussion 39. PubMed ID: 1323810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.
    Garst J; Herndon JE; Shafman T; Campagna L; Blackwell S; Padilla K; Bjurstrom T; Andrews C; Maravich-May D; Anderson E; Crawford J
    Clin Drug Investig; 2006; 26(5):257-66. PubMed ID: 17163259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group.
    Ignatiadis M; Mavroudis D; Veslemes M; Boukovinas J; Syrigos K; Agelidou M; Agelidou A; Gerogianni A; Pavlakou G; Tselepatiotis E; Nikolakopoulos J; Georgoulias V
    Clin Lung Cancer; 2005 Nov; 7(3):183-9. PubMed ID: 16354313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: a phase II study of the Southwest Oncology Group (SWOG-9229).
    Thomas CR; Giroux DJ; Stelzer KJ; Craig JB; Laufman LR; Taylor SA; Goodwin JW; Crowley JJ; Livingston RB
    Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1039-47. PubMed ID: 9539558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer.
    Bunn PA; Kelly K
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-144-S12-148. PubMed ID: 9331140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer.
    Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Kamei H; Horiguchi T; Kodani T; Maeda T; Tabata M; Shibayama T
    Cancer; 1993 Sep; 72(5):1597-601. PubMed ID: 8394202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive performance of a pharmacodynamic model for oral etoposide.
    Miller AA; Tolley EA
    Cancer Res; 1994 Apr; 54(8):2080-3. PubMed ID: 8174108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.
    Schaefer PL; Marks RS; Mahoney MR; Sloan JA; Bauman MD; Tazelaar HD; Kugler JW; Mailliard JA; Ebbert LP; Wiesenfeld M
    Am J Clin Oncol; 2003 Jun; 26(3):236-40. PubMed ID: 12796591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    Wolf M; Havemann K; Holle R; Gropp C; Drings P; Hans K; Schroeder M; Heim M; Dommes M; Mende S
    J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Phase II study of a continuous five-day intravenous infusion of cisplatin and etoposide with concurrent chest radiation therapy in limited stage small cell lung cancer].
    Sugita T; Matsunaga K; Kobayashi H; Horikawa S; Suzuki Y; Nishiyama H; Maekawa N; Matsumoto H; Okazaki M; Katagami N
    Gan To Kagaku Ryoho; 1994 Oct; 21(14):2479-83. PubMed ID: 7944494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.
    Hainsworth JD; Gray JR; Stroup SL; Kalman LA; Patten JE; Hopkins LG; Thomas M; Greco FA
    J Clin Oncol; 1997 Dec; 15(12):3464-70. PubMed ID: 9396399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ifosfamide, cisplatin, and etoposide (ICE) in the treatment of advanced non-small cell lung cancer.
    Shepherd FA; Evans WK; Goss PE; Latreille J; Logan D; Maroun J; Stewart D; Warner E; Paul K
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):54-8. PubMed ID: 1329213
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.
    Ihde DC; Mulshine JL; Kramer BS; Steinberg SM; Linnoila RI; Gazdar AF; Edison M; Phelps RM; Lesar M; Phares JC
    J Clin Oncol; 1994 Oct; 12(10):2022-34. PubMed ID: 7931470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II study of all-trans-retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma: an Eastern Cooperative Oncology Group Study.
    Kalemkerian GP; Jiroutek M; Ettinger DS; Dorighi JA; Johnson DH; Mabry M
    Cancer; 1998 Sep; 83(6):1102-8. PubMed ID: 9740074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
    Miller AA; Al Omari A; Murry DJ; Case D
    Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.
    Slevin ML; Clark PI; Joel SP; Malik S; Osborne RJ; Gregory WM; Lowe DG; Reznek RH; Wrigley PF
    J Clin Oncol; 1989 Sep; 7(9):1333-40. PubMed ID: 2549204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II feasibility study of high dose epirubicin-based regimens for untreated patients with small-cell lung cancer.
    Macchiarini P; Chella A; Riva A; Mengozzi G; Silvano G; Solfanelli S; Angeletti CA
    Am J Clin Oncol; 1990 Dec; 13(6):495-500. PubMed ID: 2173392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
    Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
    J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.